(KITS) Kits Eyecare - Ratings and Ratios
Exchange: TO • Country: Canada • Currency: CAD • Type: Common Stock • ISIN: CA49804N1042
KITS EPS (Earnings per Share)
KITS Revenue
KITS: Progressive Lenses, Contact Lenses, Eyeglasses, Frames
Kits Eyecare Ltd. is a digitally-driven eyecare platform operating in North America, specifically the United States and Canada, offering a range of eyewear products including progressive and contact lenses, eyeglasses, and frames under its in-house KITS brand, alongside distributing products from other prominent brands. The companys robust e-commerce infrastructure is supported by a network of websites such as KITS.com, KITS.ca, OptiContacts.com, and ContactsExpress.ca, catering to a diverse customer base. Since its inception in 2002, Kits Eyecare has established itself as a significant player in the eyecare industry, with its headquarters in Vancouver, Canada.
From a business perspective, Kits Eyecares model is centered around leveraging digital platforms to offer a wide array of eyecare products, thereby capitalizing on the growing trend of online shopping. The companys ability to manufacture its own brand products while also acting as a distributor for other brands allows for a diversified product portfolio, potentially insulating it from market fluctuations in specific product categories.
Analyzing the provided technical data, it is evident that KITS has shown a positive trend, with its last price being $11.60, above both its 20-day and 50-day Simple Moving Averages (SMA) of $11.37 and $10.81, respectively. The stock is also significantly above its 200-day SMA of $9.77, indicating a strong uptrend. The Average True Range (ATR) stands at 0.61, or 5.23% of the last price, suggesting moderate volatility. Given these indicators, a forecast based on technical analysis would suggest continued upward momentum, potentially testing the 52-week high of $12.42.
From a fundamental standpoint, Kits Eyecares market capitalization stands at $366.48M CAD, with a P/E ratio of 127.22 and a forward P/E of 65.36, indicating high expectations for future earnings growth. The Return on Equity (RoE) is 5.74%, which, while not exceptionally high, is positive. Combining fundamental and technical analysis, a forecast for KITS could be cautiously optimistic, driven by the companys strong online presence, diversified product offerings, and positive technical indicators. However, the high P/E ratios suggest that the stocks current valuation is heavily dependent on future growth expectations, making it crucial for the company to continue delivering on its growth potential.
Given the current technical and fundamental data, a potential forecast for KITS could involve reaching or slightly surpassing its 52-week high in the near term, driven by continued investor optimism and the companys operational performance. However, any forecast is contingent upon the companys ability to meet its future earnings expectations and navigate the competitive eyecare market effectively.
Additional Sources for KITS Stock
KITS Stock Overview
Market Cap in USD | 319m |
Sector | Consumer Cyclical |
Industry | Specialty Retail |
GiC Sub-Industry | Other Specialty Retail |
IPO / Inception |
KITS Stock Ratings
Growth Rating | 38.1 |
Fundamental | 27.0 |
Dividend Rating | 0.0 |
Rel. Strength | 44.6 |
Analysts | - |
Fair Price Momentum | 13.19 CAD |
Fair Price DCF | 2.66 CAD |
KITS Dividends
Currently no dividends paidKITS Growth Ratios
Growth Correlation 3m | 75% |
Growth Correlation 12m | 42.5% |
Growth Correlation 5y | 56% |
CAGR 5y | 9.79% |
CAGR/Max DD 5y | 0.13 |
Sharpe Ratio 12m | 0.14 |
Alpha | 52.75 |
Beta | 0.890 |
Volatility | 41.57% |
Current Volume | 17.7k |
Average Volume 20d | 18.4k |
As of June 24, 2025, the stock is trading at CAD 13.72 with a total of 17,725 shares traded.
Over the past week, the price has changed by +0.96%, over one month by +3.24%, over three months by +17.26% and over the past year by +63.53%.
Neither. Based on ValueRay´s Fundamental Analyses, Kits Eyecare is currently (June 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 26.99 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of KITS is around 13.19 CAD . This means that KITS is currently overvalued and has a potential downside of -3.86%.
Kits Eyecare has no consensus analysts rating.
According to our own proprietary Forecast Model, KITS Kits Eyecare will be worth about 15 in June 2026. The stock is currently trading at 13.72. This means that the stock has a potential upside of +9.26%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | 17.8 | 29.7% |
Analysts Target Price | - | - |
ValueRay Target Price | 15 | 9.3% |